| 5,797 | 196 | 709 |
| 下载次数 | 被引频次 | 阅读次数 |
肺癌是起源于支气管黏膜、腺体或肺泡上皮的肺部恶性肿瘤。随着人口老龄化和环境污染等因素的日益严重,肺癌已经成为我国发病率和死亡率最高的恶性肿瘤,严重危害人民的生命健康。然而对于肺癌的中西医结合诊疗,目前国内尚无全国性、规范化的共识指南。为了推广肺癌的规范化中西医诊治理念、提高我国在该领域的诊治水平,在国家中医药管理局医政司统筹安排下,广州中医药大学第一附属医院联合中山大学附属肿瘤医院的肿瘤专家,结合重大疑难疾病中西医临床协作试点项目(肺癌)的主要成果,编写了该共识。
Abstract：Lung cancer is a pulmonary malignant tumor originating from bronchial mucosa, gland or alveolar epithelium. With the aging of population and the worsening of environmental pollution and other factors, lung cancer has been the cancer with the highest incidence and mortality in China,which seriously endangers human health. However,there is no national and standardized consensus guide for the diagnosis and treatment of lung cancer till now. To promote the standardization of integrated traditional Chinese and western medicine treatment of lung cancer and to increase the level of the diagnosis and treatment in this field in China,the experts specialized in oncology from the First Affiliated Hospital of Guangzhou University of Chinese Medicine and from Cancer Hospital Affiliated to Sun Yat-sen University write the consensus by absorbing the main achievements in pilot project of clinical collaboration for treatment of major complicated and refractory diseases with integrated traditional Chinese and western medicine(lung cancer), and under the overall arrangement of the Department of Medical Administration of National Administration of Traditional Chinese Medicine.
[1]郑荣寿，孙可欣，张思维，等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2019,41(1):19-28.
[2]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[3]林丽珠主编.肿瘤中西医结合治疗学[M].北京：人民军医出版社，2013:140.
[4]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）原发性非小细胞肺癌诊疗指南[J].2020.
[5]NCCN Clinical Practice Guidelines in Oncology.Non-Small Cell Lung Cancer(Version 6,2020)[Z].https://www.nccn.org,Access.
[6]NCCN Clinical Practice Guidelines in Oncology.Small Cell Lung Cancer(Version 4,2020)[Z].https：//www.nccn.org,Access.
[7]林洪生主编.恶性肿瘤中医诊疗指南[M].北京：人民卫生出版社，2014:250-252.
[8]WU J,LIU Y,FANG C,et al.Traditional Chinese Medicine Preparation Combined Therapy May Improve Chemotherapy Efficacy:A Systematic Review and Meta-Analysis[J].Evid Based Complement Alternat Med,2019,2019:5015824.
[9]CHEN Z Q,LI Z Y,YANG C Z,et al.Chinese herbal medicine for epidermal growth factor receptor inhibitor-induced skin rash in patients with malignancy:An updated meta-analysis of 23randomized controlled trials[J].Complement Ther Med,2019,47:102167.
[10]王学谦，侯炜，郑佳彬，等.中医综合治疗方案维持治疗晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究[J].中医杂志，2020,61(8):690-694.
[11]徐剑焜，陈汉锐，林丽珠.林丽珠教授中西医结合治疗肺癌临床经验[J].辽宁中医药大学学报，2019,21(11):192-195.
[12]林丽珠，肖志伟，张少聪主编.中医治肿瘤理论及验案[M].北京：中国中医药出版社，2016.
[13]叶欣，范卫君，王徽，等.热消融治疗原发性和转移性肺部肿瘤专家共识（2017年版）[J].中国肺癌杂志，2017,20(7):433-445.
[14]中国抗癌协会肺癌专业委员会，中华医学会肿瘤学分会肺癌学组.Ⅲ期非小细胞肺癌多学科诊疗专家共识（2019版）[J].中华肿瘤杂志，2019,41(12):881-890.
[15]ANTONIA S J,VILLEGAS A,DANIEL D,et al.Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer[J].N Engl J Med,2017,377(20):1919-1929.
[16]徐琛，张会然，蔡志刚.中心气道狭窄的介入治疗选择[J].国际呼吸杂志，2018,38(23):1835-1840.
[17]LEE C K,WU Y L,DING P N,et al.Impact of Specific Epidermal Growth Factor Receptor(EGFR)Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer:A Meta-Analysis[J].J Clin Oncol,2015,33(17):1958-1965.
[18]YANG J C,WU Y L,SCHULER M,et al.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma(LUX-Lung 3 and LUX-Lung 6):analysis of overall survival data from two randomised,phase 3 trials[J].Lancet Oncol,2015,16(2):141-151.
[19]SORIA J C,OHE Y,VANSTEENKISTE J,et al.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,378(2):113-125.
[20]HONG S,GAO F,FU S,et al.Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer[J].JAMA Oncol,2018,4(5):739-742.
[21]WANG Z,CHENG Y,AN T,et al.Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for firstline gefitinib treatment in patients with advanced lung adenocarcinoma(BENEFIT):a phase 2,single-arm,multicentre clinical trial[J].Lancet Respir Med,2018,6(9):681-690.
[22]AHN M J,CHIU C H,CHENG Y,et al.Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC:The AURA Leptomeningeal Metastases Analysis[J].J Thorac Oncol,2020,15(4):637-648.
[23]WU Y L,AHN M J,GARASSINO M C,et al.CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced NonSmall-Cell Lung Cancer:Data From a Randomized Phase III Trial(AURA3)[J].J Clin Oncol,2018,36(26):2702-2709.
[24]CHO J H,LIM S H,AN H J,et al.Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFRMutations:A Multicenter,Open-Label,Phase II Trial(KCSG-LU15-09)[J].J Clin Oncol,2020,38(5):488-495.
[25]YANG J C,SCHULER M,POPAT S,et al.Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations:ADatabase of 693 Cases[J].J Thorac Oncol,2020,15(5):803-815.
[26]PETERS S,CAMIDGE D R,SHAW A T,et al.Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer[J].N Engl J Med,2017,377(9):829-838.
[27]SOLOMON B J,MOK T,KIM D W,et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J].N Engl JMed,2014,371(23):2167-2177.
[28]SHAW A T,OU S H,BANG Y J,et al.Crizotinib in ROS1-rearranged non-small-cell lung cancer[J].N Engl J Med,2014,371(21):1963-1971.
[29]RECK M,RODRíGUEZ-ABREU D,ROBINSON A G,et al.Pembrolizumab versus Chemotherapy for PD-L1-Positive NonSmall-Cell Lung Cancer[J].N Engl J Med,2016,375(19):1823-1833.
[30]GAINOR J F,SCHNEIDER J G,GUTIERREZ M,et al.Nivolumab(NIVO)plus ipilimumab(IPI)with two cycles of chemotherapy(chemo) in first-line metastatic non-small cell lung cancer(NSCLC):Check Mate 568 Part 2[J].Journal of Clinical Oncology,2020,38(15):suppl.9560.
[31]GANDHI L,RODRíGUEZ-ABREU D,GADGEEL S,et al.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,378(22):2078-2092.
[32]PAZ-ARES L,LUFT A,VICENTE D,et al.Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer[J].NEngl J Med,2018,379(21):2040-2051.
[33]WEST H,MCCLEOD M,HUSSEIN M,et al.Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer(IMpower130):a multicentre,randomised,open-label,phase3 trial[J].Lancet Oncol,2019,20(7):924-937.
[34]LU S,CHEN Z,HU C,et al.Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung-A Multicenter,Openlabel,Randomized,Phase III Trial[J].J Thorac Oncol,2018,13(11):1743-1749.
[35]HAN B,LI K,WANG Q,et al.Effect of Anlotinib as a ThirdLine or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer:The ALTER 0303 Phase3 Randomized Clinical Trial[J].JAMA Oncol,2018,4(11):1569-1575.
[36]YIN X,YAN D,QIU M,et al.Prophylactic cranial irradiation in small cell lung cancer:a systematic review and meta-analysis[J].BMC Cancer,2019,19(1):95.
[37]HORN L,MANSFIELD A S,SZCZ?SNA A,et al.First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer[J].N Engl J Med,2018,379(23):2220-2229.
[38]PAZ-ARES L,DVORKIN M,CHEN Y,et al.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN):a randomised,controlled,open-label,phase 3 trial[J].Lancet,2019,394(10212):1929-1939.
[39]邓铁涛主编.中医诊断学[M].上海：上海科学技术出版社，2006.
[40]张伯礼主编.中医内科学[M].北京：中国中医药出版社，2012.
[41]周岱翰主编.中医肿瘤学[M].北京：中国中医药出版社，2011.
[42]常青主编.常青治癌临证心法[M].北京：中国中医药出版社，2013.
[43]顾恪波主编.孙桂芝辨治十五种恶性肿瘤临床实录[M].北京：中国中医药出版社，2013:98-107.
[44]席彩霞，杨国泉，李正国，等.鹤蟾片维持治疗中晚期非小细胞肺癌的临床观察[J].肿瘤防治研究，2011,38(10):1170-1172.
[45]任玮.化疗联合康莱特软胶囊治疗晚期非小细胞肺癌的临床效果研究[J].黑龙江科学，2019,10(18):36-37.
[46]骆许静，马耀先，孙桢，等.消癌平片联合PC方案治疗晚期非小细胞肺癌的临床研究[J].现代药物与临床，2019,34(2):424-428.
[47]吴忠，李响，刘莹，等.安康欣胶囊联合顺铂在非小细胞肺癌辅助化疗中的应用效果[J].中国实用医药，2018,13(27):4-5.
[48]于同月，崔昊震，张松男，等.参一胶囊对晚期非小细胞肺癌临床化疗效果及免疫功能的影响分析[J].中国免疫学杂志，2018,34(7):1012-1016.
[49]蔡华荣，张海梅.复方红豆杉胶囊用于非小细胞肺癌术后转移患者维持治疗效果观察[J].现代中西医结合杂志，2019,28(15):1618-1621,1651.
[50]李斐斐，崔一鸣，陈露，等.益肺清化颗粒治疗非小细胞肺癌研究进展[J].中华中医药杂志，2013,28(7):2067-2070.
[51]陈石秀，陈佳蕾，谢瑞芳，等.基于网络药理学的金复康口服液治疗非小细胞肺癌机制[J].中成药，2019,41(7):1547-1555.
[52]关洁珊，罗智杰，肖志伟，等.正元胶囊防治肺腺癌A549移植瘤裸鼠化疗相关性疲劳的疗效及机制研究[J].广州中医药大学学报，2020,37(5):929-937.
[53]马代远，谭榜宪，柳弥，等.回生口服液联合单药奈达铂同步放化疗治疗不可切除局部晚期非小细胞肺癌[J].第三军医大学学报，2013,35(2):179-181.
[54]李泽云，陈芝强，高天琦，等.康莱特注射液联合化疗对晚期非小细胞肺癌患者疗效和不良反应的Meta分析[J].中国民族民间医药，2018,27(19):49-55.
[55]伍家鸣，王菁，林丽珠，等.艾迪注射液联合一线化疗方案治疗非小细胞肺癌临床疗效的Meta分析[J].中成药，2017,39(6):1323-1328.
[56]黎鹏，肖志伟，林丽珠.鸦胆子油乳联合多西紫杉醇+顺铂方案治疗非小细胞肺癌临床评价[J].中国药业，2018,27(15):43-45.
[57]陈汉锐，田华琴，陈志明，等.康艾注射液联合单药化疗治疗老年晚期非小细胞肺癌的有效性和安全性[J].实用医学杂志，2018,34(2):316-319.
[58]段惠龙，李雪石，高军军，等.华蟾素注射液联合多西他赛治疗老年晚期非小细胞肺癌的效果[J].临床医学研究与实践，2018,3(6):20-21.
[59]程正军，席芙蓉.参芪扶正注射液联合化疗治疗中晚期非小细胞肺癌（气虚）随机平行对照研究[J].实用中医内科杂志，2017,31(12):43-45.
[60]雷俊华，刘韵，曾江正，等.榄香烯注射液联合化疗对晚期非小细胞肺癌患者免疫功能及疗效的影响[J].临床肿瘤学杂志，2018,23(2):160-163.
[61]黎鹏，黄学武，林丽珠.中药外洗预防含紫杉醇方案化疗周围神经毒性疗效观察[J].医药前沿，2014,(18):266-267.
[62]肖志伟，杨才志，何灿封，等.健脾生髓膏方治疗肺癌患者化疗相关性疲乏的疗效观察[J].中医肿瘤学杂志，2019,1(3):24-29.
[63]中国抗癌协会肺癌专业委员会.EGFR-TKI不良反应管理专家共识[J].中国肺癌杂志，2019,22(2):57-81.
[64]林丽珠.中医药在EGFR-TKIs相关不良反应管理中的应用[J].中国中西医结合杂志，2019,39(2):144-147.
基本信息:
DOI：10.19811/j.cnki.ISSN2096-6628.2021.06.001
中图分类号:R734.2
引用信息:
[1]林丽珠,王思愚,黄学武.肺癌中西医结合诊疗专家共识[J].中医肿瘤学杂志,2021,3(06):1-17.DOI:10.19811/j.cnki.ISSN2096-6628.2021.06.001.
基金信息:
重大疑难疾病中西医临床协作试点项目（肺癌）; 中医药循证能力建设项目（编号：2019XZZX-ZL001）
2021-11-25
2021-11-25